Physician profile
Gul Khan
NPI 1891942819
$6,619.80
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $224 · 2021: $3,475 · 2022: $2,623 · 2023: $128 · 2024: $25.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,198.87 | 2021-2022 | |
| Olympus Corporation of The Americas | $1,197.46 | 2022 | |
| Glaxosmithkline, LLC. | $679.79 | 2019-2023 | Trelegy Ellipta |
| Electromed, INC. | $95.45 | 2022 | |
| Philips North America LLC | $93.98 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $83.71 | 2020-2023 | Breztri |
| Sunovion Pharmaceuticals INC. | $60.94 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.72 | 2022 | |
| Merck Sharp & Dohme LLC | $27.50 | 2019-2020 | |
| Erbe USA INC | $25.00 | 2024 | |
| Covis Pharma Gmbh | $24.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.07 | 2022 | |
| Harmony Biosciences LLC | $19.24 | 2021 | |
| Gilead Sciences, INC. | $18.95 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $18.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.